MBLY250117C20500
- 0.01
- 0.000.00%
Mobileye Global Newsroom
Mobileye Global, Inc. Class A (MBLY) Receives a Hold From RBC Capital
Earnings Preview: MBLY to Report Financial Results Pre-market on January 30
$Mobileye Global(MBLY.US)$ is scheduled to release its financial results pre-market on January 30 ET. Earnings PreviewAnalysts estimate $Mobileye Global(MBLY.US)$ to post revenue of USD478.24M for 202
Catalyst Watch: Microsoft, Meta, and Tesla Report, FOMC and a Chinese New Year Wildcard
Analysts Estimate Mobileye Global (MBLY) to Report a Decline in Earnings: What to Look Out for
Barclays Maintains Mobileye Global(MBLY.US) With Buy Rating, Maintains Target Price $22
Mobileye Is Maintained at Overweight by Barclays
Mobileye Global Analyst Ratings
Barclays Maintains Mobileye Global(MBLY.US) With Buy Rating, Raises Target Price to $22
Why Mobileye Global Inc. (MBLY) Received Analyst Approval This Week?
Mobileye Is Maintained at Neutral by UBS
Oppenheimer Maintains Mobileye Global(MBLY.US) With Buy Rating, Maintains Target Price $28
UBS Maintains Mobileye Global(MBLY.US) With Hold Rating, Raises Target Price to $17
Mobileye Initiated at Outperform by Oppenheimer
Express News | Mobileye Global Inc : UBS Raises Target Price to $17 From $14
Oppenheimer Initiates Mobileye Global(MBLY.US) With Buy Rating, Announces Target Price $28
A Closer Look at Mobileye Global's Options Market Dynamics
Press Release: Mobileye Announces Timing of Its Fourth Quarter and Full Year 2024 Results
Mobileye Global Inc.'s (NASDAQ:MBLY) Profit Outlook
Mobileye Announces Timing of Its Fourth Quarter and Full Year 2024 Results
U.S. Stock Market Insights | Delta Air Lines has scored big! Stock prices hit a new high, with performance and outlook both exceeding expectations; a $16.4 billion acquisition of Calpine, Energy giant CEG surged by 25.16%.
The Medical merger and acquisition frenzy has started again! It is rumored that Johnson & Johnson is in talks to acquire the biopharmaceutical company Intra-Cellular Therapies Inc., which focuses on treating central nervous system diseases, and its stock price has soared nearly 15%.